A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
复制标题
DOI：
10.1101/2020.05.21.109546
复制
发表时间：
2020-08-13
影响因子：
16.6
通讯作者：
Shi, Pei-Yong
中科院分区：
文献类型：
--
作者：
Muruato, Antonio E;Fontes-Garfias, Camila R;Shi, Pei-Yong
病毒中和仍然是确定抗体功效的金标准。因此，迫切需要一种高通量检测SARS-CoV-2中和抗体的方法用于COVID-19血清学诊断、恢复期血浆治疗和疫苗开发。在这里，我们报告了一种基于荧光的SARS-CoV-2中和试验，该试验检测COVID-19患者标本中的SARS-CoV-2中和抗体，并产生与空斑减少中和试验（血清学检测的金标准）相当的结果。我们的方法提供了一个快速平台，可以扩展到筛查人们对COVID-19的抗体保护，这是安全重新开放当地社区所必需的关键参数。病毒中和仍然是确定抗体效力的金标准。因此，迫切需要一种高通量检测SARS-CoV-2中和抗体的方法用于COVID-19血清学诊断、恢复期血浆治疗和疫苗开发。在这里，我们报告了一种基于荧光的SARS-CoV-2中和试验，该试验检测COVID-19患者标本中的SARS-CoV-2中和抗体，并产生与空斑减少中和试验（血清学检测的金标准）相当的结果。基于荧光的中和试验特异性用于测量COVID-19中和抗体，而不会与其他病毒、细菌或寄生虫感染的患者标本发生交叉反应。总的来说，我们的方法提供了一个快速的平台，可以扩展到筛查人们对COVID-19的抗体保护，这是安全重新开放当地社区所必需的关键参数。
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.